“Unprecedented,” “remarkable” and “transformative” were just a few of the descriptives tossed out by Wall Street analysts in response to Revolution Medicines Inc.’s phase III readout, showing RAS inhibitor daraxonrasib hit its overall survival and progression-free survival endpoints in previously treated patients with metastatic pancreatic ductal adenocarcinoma. With an overall survival of 13.2 months, nearly double the 6.7 months seen in the chemotherapy arm, daraxonrasib largely beat expectations, and prompted Revolution Medicines to determine the interim analysis results as final. The company anticipates as its next step to submit these data to regulatory authorities and, with the drug’s previous inclusion in the FDA commissioner’s national priority voucher pilot program, could see U.S. approval before the end of 2026. Shares of Revolution (NASDAQ:RVMD) were trading up 38% at midday.

Allogene soars on phase II cema-cel results in LBCL

Shares of Allogene Therapeutics Inc. (NASDAQ:ALLO) were trading at $4, up $1.27, or 46%, on data from the planned interim futility analysis of its pivotal, randomized phase II Alpha3 trial in first-line consolidation large B-cell lymphoma (LBCL). At the cutoff point – i.e., when the 24th patient completed the day 45 minimal residual disease (MRD) assessment – 58.3% (seven out of 12) of patients in the CAR T-therapy cemacabtagene ansegedleucel (cema-cel) arm achieved negativity compared to 16.7% (two of 12) in the observation arm, for a 41.6% absolute difference. South San Francisco-based Allogene noted that, based on scientific literature, a difference of 25-30% in MRD clearance at study completion could translate into meaningful clinical benefit with cema-cel in LBCL.

Regeneron enters radiopharma space via Telix deal

Regeneron Pharmaceuticals Inc. is entering the radiopharmaceutical space via a collaboration with Telix Pharmaceuticals Ltd. to jointly develop and commercialize next-generation radiopharmaceutical therapies. Rather than a conventional licensing arrangement, the companies will codevelop and co-commercialize multiple programs under a 50-50 cost- and profit-sharing model. Melbourne, Australia-based Telix will receive AU$57 million (US$40 million) up front for four initial programs covering multiple solid tumor targets drawn from Regeneron’s antibody portfolio. Tarrytown, N.Y.-based Regeneron has the option to expand the collaboration to include four additional programs. If Telix opts out of the co-funding model for a given program, it would instead be eligible to receive up to $535 million in development and commercial milestones, plus royalties. Across the initial four programs, the deal carries more than $2.1 billion in potential milestone payments, with the overall value doubling to $4.2 billion if the option for four additional programs is exercised under the same terms.

Revenio speeds up growth, acquiring Visionix for €290M

Revenio Group Oyj has agreed to acquire ophthalmic diagnostics company Visionix International SAS for an enterprise value of €290 million (US$339 million) as it looks become a leading player in the global eye care market. The deal expands Revenio’s offering with a highly complementary product and software portfolio, including optical coherence tomography equipment, an important and growing segment that is new to the company.

Synox en route to approval on positive phase III results for TGCT

Synox Therapeutics Ltd. is preparing to file for FDA approval of emactuzumab in treating tenosynovial giant cell tumor (TGCT), after announcing positive top-line phase III results. The rare disease indication is a somewhat crowded market with two marketed therapies and a third approval imminent, but Synox says the trial results show its CSF-1R (colony stimulating factor-1 receptor) inhibitor has a faster onset, more durable effect and better safety profile than the competition. The length of treatment effect seen with intravenously administered emactuzumab could potentially avoid the need for chronic treatment, as is the case for the three other, orally administered CSF-1R inhibitors, according to Dublin-based Synox.

Spyre’s SPY-001 induces better outcomes in ulcerative colitis

Spyre Therapeutics Inc. hit its primary endpoint in the initial part of its phase II Skyline platform trial testing the induction phase treatment of SPY-001 in patients with moderately to severely active ulcerative colitis. After 12 weeks, the extended half-life antibody targeting α4β7 reduced Robart’s Histopathology Index score by 9.2 points (p-value less than 0.0001). The drug also improved secondary endpoints with a 40% clinical remission rate, a 51% endoscopic improvement rate and a change in the modified Mayo score of -3.7. Shares of Spyre (NASDAQ:SYRE) were trading up $12.89, or 25%, to $64.18 in early afternoon trading.

Biopharma deal value gains 17% in early 2026

Biopharma deal value totaled $18.05 billion in March 2026, marking a pullback from the elevated $30.01 billion recorded in February and $31.16 billion in January, but still within historical norms. For the first quarter (Q1), 2026 deal value increased 17% year over year to $79.22 billion, up from $67.6 billion in Q1 2025.

Lipid reading: Street not deaf to ACC data

Abstracts released ahead of the American College of Cardiology (ACC) meeting held in late March in New Orleans, along with the start of dosing near the end of January in Novartis AG’s phase IIb trial with siRNA therapy DII-235, also known as BW-20829, perked up the already-lively lipids/heart space. Novartis, partnered with Argo Biopharmaceutical Co. Ltd., is testing DII-235 in adults with elevated lipoprotein(a), also called Lp(a), and atherosclerotic cardiovascular disease. DII-235 is the sixth asset in Argo's pipeline to enter mid-stage global clinical development. The attention-getting ACC abstracts included two related to Merck & Co. Inc.’s enlicitide decanoate and one on subcutaneously injected Repatha (evolocumab, Amgen Inc.), the monoclonal antibody targeting PCSK9 first approved by the U.S.

Stryker agrees to buy Amplitude Vascular Systems for IVL tech

Stryker Corp. has signed a definitive agreement to acquire Amplitude Vascular Systems Inc. (AVS) in a bid to strengthen its peripheral vascular portfolio, by adding a revascularization technology. The financial terms were not disclosed. AVS is developing the Pulse IVL, a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified arterial disease, in a rapidly growing market with only a few players.

CMS looks to bring Rx prior authorization into digital age

In a move intended to give patients quick access to drugs their doctors prescribe, the U.S. CMS is proposing a rule giving insurers no more than 24 hours to respond to urgent prior authorization requests and 72 hours for standard requests. The rule also would require full disclosure of claims denials and appeals outcomes. “Patients should not have to wait days or weeks for approval to start the medication their doctor prescribed,” CMS Administrator Mehmet Oz said. “This proposal moves prior authorization into the digital age, replacing fax machines and fragmented systems with real-time electronic workflows. We are standardizing the process, increasing transparency, and ensuring providers can focus on caring for patients instead of navigating red tape.”

GLP-1R drug response tied to variants in target genes

About 40% of adults in the U.S. are considered to be living with obesity, a condition that impacts the risk of several health disorders such as type 2 diabetes or cardiovascular disease, and may be detrimental to health even in the absence of metabolic dysfunction. The development of glucagon-like peptide 1 receptor (GLP-1R) agonists, such as semaglutide and tirzepatide, has been a game changer in the clinical management of overweight and obesity, but there is interpersonal variability in efficacy of these medications for weight loss, as well as in the incidence of undesired side effects. GLP-1 and gastric inhibitory polypeptide (GIP) are two primary incretins secreted from the gastrointestinal tract after food consumption that stimulate pancreatic β-cell proliferation and insulin secretion, delaying gastric emptying and suppressing appetite. In an article appearing in Nature on April 8, 2026, investigators from the 23andMe Research Institute shed some light on how variations in the GLP-1R and GIP receptor (GIPR) genes impact their effectiveness and the occurrence of side effects.

Also in the news

Ailux, Alligator, Apotex, Boxspine, Cardiff, Circa, Deepcyte, Difgen, Duality Biologics, Gan & Lee, Grail, GSK, Hologic, Johnson & Johnson, Junction, JW Pharmaceutical, Lynk, Medcad, Sibel, Sobi, Telix, Theralase, Verastem, Vivatides, Whitehawk